Avalon GloboCare Corp. (NASDAQ: ALBT) is a commercial stage company dedicated to developing and delivering innovative, transformative, precision diagnostics and clinical laboratory services. Avalon is establishing a leading role in the innovation of diagnostic testing, utilizing proprietary technology to deliver precise, genetics-driven results. The Company also provides laboratory services, offering a broad portfolio of diagnostic tests including drug testing, toxicology, and a broad array of test services, from general bloodwork to anatomic pathology, and urine toxicology. For more information about Avalon GloboCare, please visit www.avalon-globocare.com.
Company profile
Ticker
ALBT
Exchange
Website
CEO
David K. Jin
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
GLOBAL TECHNOLOGIES CORP
SEC CIK
ALBT stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
27 Mar 24
8-K
Entry into a Material Definitive Agreement
22 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
9 Nov 23
D
$700.00 k in Convertible Debt, sold $700.00 k, 2 investors
20 Oct 23
8-K
Entry into a Material Definitive Agreement
13 Oct 23
8-K
Departure of Directors or Certain Officers
13 Oct 23
ARS
2022 FY
Annual report to shareholders
8 Sep 23
DEF 14A
Definitive proxy
8 Sep 23
8-K
Patent for Multiple Novel QTY-Code Modified Cytokine and Chemokine Protein Receptor Molecules
5 Sep 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 341.77 k | 341.77 k | 341.77 k | 341.77 k | 341.77 k | 341.77 k |
Cash burn (monthly) | 103.81 k | 299.68 k | 495.03 k | 769.17 k | 449.55 k | 639.39 k |
Cash used (since last report) | 619.53 k | 1.79 mm | 2.95 mm | 4.59 mm | 2.68 mm | 3.82 mm |
Cash remaining | -277.76 k | -1.45 mm | -2.61 mm | -4.25 mm | -2.34 mm | -3.47 mm |
Runway (months of cash) | -2.7 | -4.8 | -5.3 | -5.5 | -5.2 | -5.4 |
Institutional ownership, Q2 2023
1.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 9 |
Opened positions | 1 |
Closed positions | 5 |
Increased positions | 1 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 197.95 mm |
Total shares | 128.55 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 84.45 k | $130.05 mm |
STT State Street | 19.12 k | $29.45 mm |
Geode Capital Management | 17.10 k | $26.33 mm |
Tower Research Capital | 4.90 k | $7.54 mm |
BLK Blackrock | 2.75 k | $4.24 mm |
MS Morgan Stanley | 200.00 | $308.00 k |
FMR | 19.00 | $29.00 k |
Sound Income Strategies | 10.00 | $15.00 k |
RY Royal Bank Of Canada | 9.00 | $0.00 |
Proequities | 0.00 | $0.00 |